Trial Profile

TEMOkids Study: A Population Pharmacokinetic, Acceptability and Safety Study for KIMOZO, a Paediatric Oral Suspension of Temozolomide

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Temozolomide (Primary)
Indications Cancer; Ewing's sarcoma; Glioma; Medulloblastoma; Neuroblastoma; Rhabdomyosarcoma
Focus Pharmacokinetics; Registrational
Acronyms TEMOkids
Sponsors ORPHELIA Pharma

Most Recent Events

31 Jul 2025 Status changed from active, no longer recruiting to completed.
24 Oct 2023 According to an ORPHELIA Pharma media release, the company has filed a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for KIZFIZO, the first oral liquid formulation of temozolomide.
07 Jul 2023 This trial has been completed in Germany (Global end date: 3 July 2023)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com